Unicycive Therapeutics (UNCY) vs Vivani Medical (VANI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vivani Medical (VANI) has outperformed Unicycive Therapeutics (UNCY) over the past year, losing 10.9% versus a loss of 13.1%. Over five years, UNCY leads with a -84.9% price change compared with -86.0% for VANI. Vivani Medical is the larger company by market cap ($112.8 million vs $112.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | UNCY | VANI |
|---|---|---|
| Share price | $4.11 | $1.25 |
| Market cap | $112.59M | $112.75M |
| 1-day change | +0.98% | +1.63% |
| YTD return | -28.77% | 0.00% |
| 1-year return | -13.11% | -10.87% |
| 5-year return | -84.91% | -85.96% |
| Forward P/E | 2.44 | — |
| EPS (TTM) | $-1.72 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.74 | $1.92 |
| 52-week low | $3.93 | $0.923 |
| Distance from 52-week high | -52.97% | -34.90% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +591.00% | +206.40% |
| Average volume | 839.29K | 228.48K |
| Shares outstanding | 27.39M | 90.20M |
| Employees | 21 | 42 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Vivani Medical
VANI stock →Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 42 employees
UNCY vs VANI FAQ
Which is bigger, Unicycive Therapeutics or Vivani Medical?
Vivani Medical (VANI) is larger, with a market capitalization of $112.75M compared with $112.59M for Unicycive Therapeutics (UNCY).
Which stock has performed better over the past year, UNCY or VANI?
VANI returned -10.87% over the past 12 months, compared with -13.11% for UNCY (price return, excluding dividends). Past performance does not predict future results.
Are Unicycive Therapeutics and Vivani Medical in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Unicycive Therapeutics and Biotechnology: Electromedical & Electrotherapeutic Apparatus for Vivani Medical.